Predictive Oncology’s Breakthrough in Drug Repurposing Offers Hope for Patients
/in Drug repurposing, Preclinical Research/by MaxPhase 1 Soon Recruiting: MK-2400 (Ifinatamab Deruxtecan) for Metastatic Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxNewsletter 15/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! This week brings a solid batch of seven articles. From bold new strategies to cutting-edge trials, it seems that momentum is building. Stay strong and fight on! As usual, we also have a podcast if you prefer to listen […]
Phase 1 Trial: The COSMYC Trial, ZEN-3694 Combination With BAT
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 2 Trial Enrolling: Combination Therapy for Metastatic Castration-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 1 Enrolling: Sylvester Cancer Center Launches Innovative Clinical Trial for High-Grade Neuroendocrine Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxAdvancements in Delivery: Gene Therapy Could Help Prostate Cancer Treatment
/in CRISPR, Delivery, Preclinical Research/by MaxUpdate: FC705 Signals a Leap Forward in Prostate Cancer Therapy, Outperforming Pluvicto
/in Clinical Trial, Metastatic, Phase 2/by MaxNew Molecule Boosts Vaccine Power Against Cancer and Viruses, In Vivo Study
/in Immunotherapy, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Phase 1/2 Trial Combines GI-102 With Pasritamig to Strengthen T-Cell Immunotherapy in Advanced Prostate Cancer October 13, 2026
- UPDATE: LUNAR Trial Follow-Up Strengthens Case for Earlier PSMA Radioligand Therapy October 13, 2026
- Doxycycline Shows Preclinical Activity Against Prostate Cancer Bone Metastasis October 13, 2026
- New Randomized Phase 2 Trial Tests Vaccine Plus PSMA×CD3 Immunotherapy in Biochemical Recurrence October 13, 2026